Literature DB >> 3878242

Normal T cell subsets and lymphocyte activity in multiple sclerosis.

M M Albala, D Davignon, L D Fast, D D Clark.   

Abstract

Nine patients with either chronic progressive or relapsing/remitting multiple sclerosis were treated with several courses of lymphopheresis. The lymphocytes obtained by this procedure showed a significantly lower percentage of OKT3+ cells than normal controls at the beginning of therapy. This percentage increased to normal levels after five lymphopheresis treatments and then decreased during the last stages of treatment. Patients had normal levels of OKT4+ and OKT8+ cells compared to controls and these percentages showed no statistically significant changes during the course of treatment. The proliferative response of patient's lymphocytes after stimulation with concanavalin A, PHA and alloantigen was not significantly different from normal controls and these responses were unchanged during the lymphopheresis treatment. Natural killer cell activity was also normal in our patients. The results reported in this study do not suggest a basic T cell abnormality in our patients with multiple sclerosis. Furthermore, the lymphopheresis treatments did not induce any significant change in T cell numbers or functional activity in vitro.

Entities:  

Mesh:

Year:  1985        PMID: 3878242      PMCID: PMC1577277     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  25 in total

1.  The PHA dose-response curve: validation of the use of logarithmic graph paper by computer analysis results.

Authors:  J B Ziegler; P J Hansen; W A Davies; R Penny
Journal:  J Immunol       Date:  1974-12       Impact factor: 5.422

2.  Separation of functional subsets of human T cells by a monoclonal antibody.

Authors:  E L Reinherz; P C Kung; G Goldstein; S F Schlossman
Journal:  Proc Natl Acad Sci U S A       Date:  1979-08       Impact factor: 11.205

3.  Lymphocytapheresis in chronic progressive multiple sclerosis: results of a preliminary trial.

Authors:  J Rose; H Klein; J Greenstein; D McFarlin; L Gerber; H McFarland
Journal:  Ann Neurol       Date:  1983-11       Impact factor: 10.422

4.  A monoclonal antibody reactive with the human cytotoxic/suppressor T cell subset previously defined by a heteroantiserum termed TH2.

Authors:  E L Reinherz; P C Kung; G Goldstein; S F Schlossman
Journal:  J Immunol       Date:  1980-03       Impact factor: 5.422

5.  Suppressor cell function in multiple sclerosis: correlation with clinical disease activity.

Authors:  J P Antel; B G Arnason; M E Medof
Journal:  Ann Neurol       Date:  1979-04       Impact factor: 10.422

6.  Antibodies to oligodendroglia in patients with multiple sclerosis.

Authors:  O Abramsky; R P Lisak; D H Silberberg; D E Pleasure
Journal:  N Engl J Med       Date:  1977-12-01       Impact factor: 91.245

7.  Loss of suppressor T cells in active multiple sclerosis. Analysis with monoclonal antibodies.

Authors:  E L Reinherz; H L Weiner; S L Hauser; J A Cohen; J A Distaso; S F Schlossman
Journal:  N Engl J Med       Date:  1980-07-17       Impact factor: 91.245

8.  Dysfunction of natural killer cells in multiple sclerosis: a possible pathogenetic factor.

Authors:  M Benczur; G G Petrányl; G Pálffy; M Varga; M Tálas; B Kotsy; I Földes; S R Hollán
Journal:  Clin Exp Immunol       Date:  1980-03       Impact factor: 4.330

9.  Isoelectric focusing of IgG eluted from multiple sclerosis and subacute sclerosing panencephalitis brains.

Authors:  D H Mattson; R P Roos; B G Arnason
Journal:  Nature       Date:  1980-09-25       Impact factor: 49.962

10.  Deficit of suppressor T cells in active multiple sclerosis.

Authors:  M A Bach; F Phan-Dinh-Tuy; E Tournier; L Chatenoud; J F Bach; C Martin; J D Degos
Journal:  Lancet       Date:  1980-12-06       Impact factor: 79.321

View more
  2 in total

1.  Dual labelling of circulating CD8 cells in patients with multiple sclerosis.

Authors:  P J Hughes; P F Kirk; D A Compston
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-01       Impact factor: 10.154

2.  Lymphocyte activating factor activity in the serum and cerebrospinal fluid of patients with multiple sclerosis.

Authors:  D Donati; P Annunziata; G C Guazzi; D Boraschi; A Tagliabue
Journal:  Ital J Neurol Sci       Date:  1990-02
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.